In Vitro Activity of Tebipenem, a New Oral Carbapenem Antibiotic, against β-Lactamase-Nonproducing, Ampicillin-Resistant Haemophilus influenzae-Reference-Cited by-同舟云学术

In Vitro Activity of Tebipenem, a New Oral Carbapenem Antibiotic, against β-Lactamase-Nonproducing, Ampicillin-Resistant Haemophilus influenzae

Published:2010-09 Issue:9 Volume:54 Page:3970-3973
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kishii Kozue¹²,Chiba Naoko¹,Morozumi Miyuki¹²,Ono Akiko¹²,Ida Takashi²,Ubukata Kimiko¹

Affiliation:

1. Laboratory of Molecular Epidemiology for Infectious Agents, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

2. Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka, Kohoku-ku, Yokohama, Kanagawa 222-8567, Japan

Abstract

ABSTRACT In vitro activity of tebipenem, a new oral carbapenem antibiotic, against clinical Haemophilus influenzae isolates was compared with those of 8 reference agents. Isolates were classified into 6 resistance classes after PCR identification of β-lactamase genes and ftsI gene mutations. For all isolates, the minimal concentration at which 90% of isolates were inhibited was lower for tebipenem than for the reference oral antibiotics, except for cefditoren. Tebipenem also showed excellent bactericidal activity against β-lactamase-nonproducing, ampicillin-resistant isolates.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00054-10

Reference12 articles.

1. Performance standard for antimicrobial susceptibility testing; 18th informational supplement. 2008

2. Hasegawa, K., K. Yamamoto, N. Chiba, R. Kobayashi, K. Nagai, M. R. Jacobs, P. C. Appelbaum, K. Sunakawa, and K. Ubukata. 2003. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb. Drug Resist.9:39-46.

3. Rapidly Increasing Prevalence of β-Lactamase-Nonproducing, Ampicillin-Resistant Haemophilus influenzae Type b in Patients with Meningitis

4. In Vitro Antibacterial Activity of LJC 11,036, an Active Metabolite of L-084, a New Oral Carbapenem Antibiotic with Potent Antipneumococcal Activity

5. In Vitro Activity of Tebipenem, a New Oral Carbapenem Antibiotic, against Penicillin-Nonsusceptible Streptococcus pneumoniae

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tebipenem pivoxil hydrobromide—No PICC, no problem!;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2021-08-17

2. Genetic characteristics and antibiotic resistance of Haemophilus influenzae isolates from pediatric patients with acute otitis media after introduction of 13-valent pneumococcal conjugate vaccine in Japan;Journal of Infection and Chemotherapy;2019-09

3. Tebipenem, the first oral carbapenem antibiotic;Expert Review of Anti-infective Therapy;2018-07-03

4. Recent updates of carbapenem antibiotics;European Journal of Medicinal Chemistry;2017-05

5. Prediction of HPLC retention times of tebipenem pivoxyl and its degradation products in solid state by applying adaptive artificial neural network with recursive features elimination;Talanta;2015-05